Revolution Medicines Inc

RVMD · NASDAQ · Healthcare / Biotechnology

172.29USD-4.06 (-2.30%)

Price History

Full chart

Market Stats

Previous Close176.35

Open176.02

Day Range168.62 – 176.06

52-Week Range56.66 – 224.31

Volume2.65M

Market Cap40.45B

P/E (TTM)0.00

Forward P/E0.00

EPS-8.99

Dividend Yield0.00%

Beta1.40

50-Day Avg200.12

200-Day Avg155.34

About

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Company Details

SectorHealthcare
IndustryBiotechnology
CEODr. Mark A. Goldsmith M.D., Ph.D.
Employees883
Headquarters700 Saginaw Drive, Redwood City, CA, United States, 94063, USA
Websitehttps://www.revmed.com

Leadership

Dr. Mark A. Goldsmith M.D., Ph.D.CEO, President & Chairman · b. 1962
Mr. Jack AndersChief Financial Officer · b. 1977
Ms. Margaret A. Horn J.D.Chief Operating Officer · b. 1963
Mr. Jeffrey Cislini J.D.Senior VP, General Counsel & Corporate Secretary · b. 1975
Dr. Stephen M. Kelsey FRC Path., FRCP, M.D.Senior Advisor · b. 1961
Dr. Martin D. Burke M.D., Ph.D.Co-Founder & Chairman of Scientific Advisory Board
Dr. Michael A. Fischbach Ph.D.Academic Co-Founder & Member of Scientific Advisory Board · b. 1981
Dr. Kevan M. Shokat Ph.D.Academic Co-Founder & Member of Scientific Advisory Board
Mr. Walter Reiher Ph.D.Chief Information Officer
Ms. Jan Smith Ph.D.Chief Scientific Officer

Financials

Income Statement

Currency: USD	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	0	20.16M	50.04M	42.98M	29.39M	35.38M	11.58M	0	0
Growth (%)	-	-	+148.16%	-14.10%	-31.62%	+20.38%	-67.27%	-100.00%	-
Cost of Revenue	26.59M	51.08M	91.75M	132.25M	186.95M	253.07M	411.24M	592.23M	16.56M
Gross Profit	-26.59M	20.16M	50.04M	42.98M	29.39M	35.38M	11.58M	-592.23M	-16.56M
Gross Margin	-	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	-	-
Operating Expense	4.54M	60.49M	104.16M	153.68M	217.40M	293.66M	498.76M	97.30M	1.17B
Operating Income	-31.13M	-40.33M	-54.12M	-110.70M	-188.01M	-258.28M	-487.19M	-689.52M	-1.18B
Operating Margin	-	-200.00%	-108.15%	-257.54%	-639.70%	-730.01%	-4207.12%	-	-
EBITDA	-29.84M	-39.91M	-48.59M	-101.91M	-179.75M	-239.47M	-430.28M	-589.02M	-1.09B
EBITDA Margin	-	-197.91%	-97.10%	-237.10%	-611.59%	-676.85%	-3715.71%	-	-
Net Income	-31.13M	-41.79M	-47.66M	-108.16M	-187.09M	-248.71M	-436.37M	-600.09M	-1.13B
Net Income Margin	-	-207.24%	-95.25%	-251.63%	-636.58%	-702.95%	-3768.28%	-	-
R&D	26.59M	51.08M	91.75M	132.25M	186.95M	253.07M	423.14M	592.23M	978.68M
R&D as % of Total Revenue	-	253.33%	183.36%	307.68%	636.09%	715.30%	3654.09%	-	-
Interest Expense	103.00K	116.00K	106.00K	71.00K	12.00K	9.66M	303.00K	0	24.23M
Interest Expense % of Total Revenue	-	0.58%	0.21%	0.17%	0.04%	27.29%	2.62%	-	-

Balance Sheet

Currency: USD	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	15.08M	170.59M	220.53M	567.40M	737.99M	811.93M	2.06B	2.56B	2.35B
Total Liabilities	10.55M	73.93M	67.99M	92.72M	135.42M	126.74M	235.51M	293.10M	723.21M
Total Equity	4.53M	96.66M	152.53M	474.68M	602.57M	685.19M	1.83B	2.27B	1.63B
Cash	9.08M	69.59M	16.66M	104.27M	108.50M	161.41M	696.15M	543.06M	383.75M
Total Debt	-	318.00K	172.00K	32.66M	66.63M	64.20M	87.94M	135.84M	158.70M
Net Debt	-9.08M	-69.44M	-16.66M	-71.60M	-41.86M	-97.21M	-608.20M	-407.22M	-225.04M

Cash Flow

Currency: USD	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	-25.15M	1.21M	-49.62M	-100.06M	-147.18M	-224.40M	-350.57M	-557.44M	-897.74M
Investing Cash Flow	-1.57M	-1.34M	-101.97M	-234.23M	-142.12M	-24.12M	-342.60M	-554.39M	118.06M
Financing Cash Flow	22.66M	60.85M	98.66M	422.78M	294.18M	301.43M	1.23B	959.41M	621.52M
Capital Expenditure	1.57M	1.50M	2.59M	2.93M	6.53M	10.82M	7.73M	10.31M	15.99M
Free Cash Flow	-26.72M	-286.00K	-52.20M	-103.00M	-153.71M	-235.22M	-358.30M	-567.74M	-913.73M
FCF to OCF	106.26%	-23.58%	105.22%	102.93%	104.44%	104.82%	102.20%	101.85%	101.78%

Earnings

Report Date	Nov 27, 2019	Mar 30, 2020	May 14, 2020	Aug 10, 2020	Nov 12, 2020	Mar 2, 2021	May 10, 2021	Aug 11, 2021	Nov 10, 2021	Feb 28, 2022	May 9, 2022	Aug 9, 2022	Nov 7, 2022	Feb 27, 2023	May 8, 2023	Aug 8, 2023	Nov 6, 2023	Feb 26, 2024	May 8, 2024	Aug 7, 2024	Nov 6, 2024	Feb 24, 2025	May 7, 2025	Aug 6, 2025	Nov 5, 2025	Feb 25, 2026	May 6, 2026	Aug 5, 2026	Nov 4, 2026
EPS Estimate	0.00	-0.41	-0.36	-0.37	-0.40	-0.38	-0.52	-0.56	-0.62	-0.64	-0.77	-0.84	-0.85	-0.82	-0.80	-0.82	-1.00	-0.88	-0.72	-0.76	-0.88	-0.96	-1.06	-1.12	-1.39	-1.58	-1.84	-1.93	-2.34
EPS Actual	-0.37	-6.52	-0.74	-0.46	-0.42	-0.52	-0.53	-0.60	-0.72	-0.71	-0.78	-0.82	-0.87	-0.63	-0.72	-0.92	-0.99	-1.14	-0.70	-0.81	-0.94	-1.12	-1.13	-1.31	-1.61	-1.86	-2.29	-2.34	-
Surprise	-	-1490.24%	-105.56%	-24.32%	-5.00%	-36.84%	-1.92%	-7.14%	-16.13%	-10.94%	-1.30%	2.38%	-2.35%	23.17%	10.00%	-12.20%	1.00%	-29.55%	2.78%	-6.58%	-6.82%	-16.12%	-6.60%	-16.96%	-15.83%	-17.72%	-24.46%	-21.24%	-
Timing	-	After-hours	After-hours	Pre-market	Pre-market	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	-	After-hours	After-hours	After-hours

Key Statistics & Ratios

Market Cap40.45B

Enterprise Value36.63B

Trailing P/E0.00

Forward P/E0.00

Price / Sales9035.10

Price / Book15.32

EPS-8.99

Book Value12.17

Revenue (TTM)742.00K

Gross Profit (TTM)-1.30B

EBITDA-1.62B

Profit Margin0.00%

Operating Margin0.00%

Return on Equity-79.09%

Return on Assets-30.12%

Shares Outstanding214.34M

Shares Float184.61M

Beta1.40

Dividend Yield0.00%

Dividend Rate0.00

Payout Ratio0.00%

Analyst Ratings

Strong Buy

Based on 25 analystsTarget 258.84

Strong Buy
19
Buy
5
Hold
1

Ownership Breakdown

Institutions: 102.33%
Insiders: 1.85%
Retail / Other: 0.00%

Top Institutional Holders

BlackRock Inc
13.70M6.39%
Farallon Capital Management, L.L.C.
13.55M6.32%
FMR Inc
12.20M5.69%
Baker Bros Advisors LP
11.44M5.34%
Jupiter Topco LLC
10.74M5.01%
Darwin Global Management, Ltd.
10.63M4.96%
HHG PLC
9.77M4.56%
Vanguard Capital Management, LLC
9.09M4.24%
Vanguard Portfolio Management, LLC
8.29M3.87%
Nextech Invest, Ltd.
7.60M3.55%
Paradigm Biocapital Advisors LP
6.36M2.97%
UBS Group AG
5.45M2.54%
State Street Corp
4.90M2.28%
Capital World Investors
4.01M1.87%
Geode Capital Management, LLC
3.94M1.84%
Wellington Management Company LLP
3.84M1.79%
JPMorgan Chase & Co
3.30M1.54%
Bvf Inc
2.97M1.38%

Top Fund Holders

Vanguard MStar Total Stk Mkt Idx Invest
6.47M3.02%
Vanguard Small Cap Index
4.58M2.14%